首页|替罗非班配合介入取栓治疗对急性缺血性脑卒中患者神经功能、凝血功能指标的影响分析

替罗非班配合介入取栓治疗对急性缺血性脑卒中患者神经功能、凝血功能指标的影响分析

扫码查看
目的 分析替罗非班配合介入取栓治疗对急性缺血性脑卒中(AIS)患者神经功能、凝血功能指标的影响。方法 选取AIS患者 80 例,随机分为对照组和观察组,各 40 例。对照组行介入取栓治疗,观察组在介入取栓基础上加以替罗非班治疗。对比两组临床疗效、神经功能[美国国立卫生研究院卒中量表(NIHSS)评分、中枢神经特异性蛋白(S100β)、脑源性神经营养因子(BDNF)、神经生长因子(NGF)]、凝血功能指标[凝血酶原时间(PT)、纤维蛋白原(FIB)、凝血酶时间(TT)、活化部分凝血活酶时间(APTT)]、炎症因子[白细胞介素-6(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)]水平、生活质量及不良事件发生情况。结果 观察组治疗总有效率 92。50%较对照组的 75。00%高(P<0。05)。治疗后,两组NIHSS评分、S100β较治疗前降低,BDNF、NGF较治疗前升高,且观察组NIHSS评分(6。59±0。97)分、S100β(0。31±0。02)μg/L较对照组的(9。41±1。25)分、(0。47±0。05)μg/L低,BDNF(46。56±4。21)ng/ml、NGF(12。41±2。57)pg/ml较对照组的(36。75±3。41)ng/ml、(8。83±2。26)pg/ml高(P<0。05)。治疗后,两组PT、APTT、TT较治疗前延长,FIB较治疗前降低,且观察组PT(12。83±2。35)s、APTT(30。48±3。71)s、TT(17。98±2。84)s较对照组的(11。27±1。95)、(26。84±3。05)、(15。39±2。18)s长,FIB(2。98±0。35)g/L较对照组的(3。53±0。61)g/L低(P<0。05)。治疗后,两组IL-6、CRP、TNF-α较治疗前降低,且观察组IL-6(67。54±8。97)pg/ml、CRP(4。69±1。05)mg/L、TNF-α(5。35±1。16)ng/ml较对照组的(86。71±11。35)pg/ml、(7。53±1。67)mg/L、(8。71±1。53)ng/ml低(P<0。05)。治疗后,两组心理功能、躯体功能、社会功能及物质生活状态评分较治疗前升高,且观察组心理功能、躯体功能、社会功能及物质生活状态评分较对照组高(P<0。05)。两组不良事件发生率对比无差异(P>0。05)。结论 替罗非班配合介入取栓治疗可保护AIS患者神经功能,改善凝血功能,控制炎症反应,提高生活质量,且无严重不良事件,临床可推广应用。
The effect analysis of tirofiban combined with interventional thrombectomy on neurological and coagulation function indicators of acute ischemic stroke patients
Objective To analyze the effect of tirofiban combined with interventional thrombectomy on neurological and coagulation function indicators of acute ischemic stroke(AIS)patients.Methods A total of 80 AIS patients were randomly divided into a control group and an observation group,with 40 patients in each group.The control group received interventional thrombectomy,while the observation group received treatment with tirofiban.Comparison was made on the clinical efficacy,neurological function[National Institutes of Health Stroke Scale(NIHSS)score,central nervous specific protein-β(S100β),brain-derived neurotrophic factor(BDNF),nerve growth factor(NGF)],coagulation function indicators[prothrombin time(PT),fibrinogen(FIB),thrombin time(TT),activated partial thromboplastin time(APTT)],inflammatory cytokine[interleukin-6(IL-6),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)]levels,quality of life,and occurrence of adverse events between two groups.Results The total effective rate of 92.50%in the observation group was higher than 75.00%in the control group(P<0.05).After treatment,NIHSS score and S100β in both groups were lower than those before treatment,and BDNF and NGF were higher than those before treatment;the observation group had NIHSS score of(6.59±0.97)points and S100β of(0.31±0.02)μg/L,which were lower than(9.41±1.25)points and(0.47±0.05)μg/L in the control group;the observation group had BDNF of(46.56±4.21)ng/ml and NGF of(12.41±2.57)pg/ml,which were higher than(36.75±3.41)ng/ml and(8.83±2.26)pg/ml in the control group(P<0.05).After treatment,PT,APTT and TT in both groups were longer than those before treatment,and FIB was lower than that before treatment;the observation group had PT of(12.83±2.35)s,APTT of(30.48±3.71)s and TT of(17.98±2.84)s,which were longer than(11.27±1.95),(26.84±3.05)and(15.39±2.18)s in the control group;FIB of(2.98±0.35)g/L in the observation group was lower than(3.53±0.61)g/L in the control group(P<0.05).After treatment,IL-6,CRP and TNF-α decreased in both groups compared with those before treatment;the observation group had IL-6 of(67.54±8.97)pg/ml,CRP of(4.69±1.05)mg/L and TNF-α of(5.35±1.16)ng/ml,which were lower than(86.71±11.35)pg/ml,(7.53±1.67)mg/L and(8.71±1.53)ng/ml in the control group(P<0.05).After treatment,the scores of psychological function,physical function,social function and material life status of the two groups were higher than those before treatment,and the scores of psychological function,physical function,social function and material life status of the observation group were higher than those of the control group(P<0.05).There was no difference in the incidence of adverse events between the two groups(P>0.05).Conclusion Tirofiban combined with interventional thrombectomy can protect the neurological function,improve coagulation function,control inflammatory response,improve quality of life in AIS patients,and have no serious adverse events.It can be widely applied in clinical practice.

Acute ischemic strokeTirofibanInterventional thrombectomyNeurological functionBrain derived neurotrophic factorThrombin time

周芳贵

展开 >

353100 福建省建瓯市立医院神经内科

急性缺血性脑卒中 替罗非班 介入取栓 神经功能 脑源性神经营养因子 凝血酶时间

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(19)